RET and acute myeloid leukemia: Elsewhere on 12p, the main frequency peak for low-level gain was located at the distal end, for which oncogenes have not been previously characterised but may include ERC1, EFCAB4B and TSPAN9. ERC1 is a translocation partner of RET in AML [44].